Press releases

• Thursday, 05 December 2019

  FerGene announces pivotal Phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS ± Ta/T1) achieving a complete response at three months

• Monday, 25 November 2019

  Ferring and Blackstone Life Sciences invest over $570 million USD in novel gene therapy for bladder cancer patients

• Tuesday, 09 July 2019

  Heat-stable carbetocin has been added to the WHO Essential Medicines List for the prevention of excessive bleeding after childbirth

• Monday, 01 July 2019

  Ferring announces changes to Executive Committee

• Wednesday, 19 June 2019

  Ferring collaboration with digital health innovators WOOM aims to help more people build families faster

• Monday, 18 March 2019

  Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries

• Tuesday, 22 January 2019

  Ferring, Rebiotix and Karolinska Institutet extend collaboration to research next generation of microbiome treatments

• Monday, 03 December 2018

  Ferring announces recipients of 2018-19 Innovation Grants

• Wednesday, 31 October 2018

  Ferring announces retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer

• Wednesday, 17 October 2018

  Ferring and Evotec form strategic research alliance in reproductive medicine and women’s health

Corporate Communications

Ferring International Center S.A.
Ch. de la Vergognausaz 50
CH-1162 Saint-Prex
Switzerland
Tel: +41 58 301 00 00
Fax: +41 58 301 00 10

Email for media enquiries only.
For other queries, please see our Contact page.